ADC Therapeutics SA (ADCT)Healthcare | Drug Manufacturers - Specialty & Generic | Epalinges, Switzerland | NYSE
1.12 USD
+0.07
(6.667%)
⇧
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 1.11 -0.01 (-0.010%) ⇩ (Aug. 27, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:37 a.m. EDT
The investment case for ADC Therapeutics is currently broken by a perfect storm of deteriorating clinical data and a collapsing market valuation. The recent underwhelming results from the LOTIS-5 trial, coupled with patient deaths in other trials, have shattered the narrative of a dominant competitive position. Fundamentally, the company is bleeding cash with negative operating margins and free cash flow, while revenue growth has stalled at a mere 2%. The balance sheet is strained with debt exceeding cash reserves, and the book value is negative. The price action reflects this structural deterioration, having lost over 90% of its value over the last five years. While there was a brief recovery in 2024, the most recent annual data shows the stock is still down significantly from its peak, and the latest year-to-date performance remains negative. The market has correctly priced in the high risk of total failure or a prolonged period of non-recovery. Options activity confirms a bearish sentiment, with traders aggressively buying puts to hedge against further declines rather than betting on a rebound. With no dividend to provide income and a very low analyst recommendation driven by fear of further clinical setbacks, the security offers no margin of safety. It is a speculative vehicle for those willing to bet on a miraculous turnaround, but for a standard investment thesis, it warrants avoidance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.994263 |
| AutoARIMA | 1.042077 |
| AutoETS | 1.042077 |
| MSTL | 1.044700 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 0.89 |
| Ljung-Box p | 0.020 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 10.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.534 |
| Market Cap | 142,987,824 |
| Forward P/E | -0.75 |
| Beta | 1.84 |
| Profit Margins | -121.77% |
| Website | https://www.adctherapeutics.com |
As of Aug. 22, 2026, 3:37 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with heavy concentration in out-of-the-money strikes ($5.00 and $7.50). This indicates a market consensus expecting further price weakness or a potential collapse, despite the stock trading near its 52-week low.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.63517916 |
| Address1 | BiopOle |
| Address2 | Route de la Corniche 3B |
| All Time High | 56.59 |
| All Time Low | 0.36 |
| Ask | 0.0 |
| Ask Size | 2,300 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 2,184,990 |
| Average Daily Volume3 Month | 1,984,522 |
| Average Volume | 1,984,522 |
| Average Volume10Days | 2,184,990 |
| Beta | 1.835 |
| Bid | 0.0 |
| Bid Size | 5,500 |
| Board Risk | 7 |
| Book Value | -1.791 |
| City | Epalinges |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.12 |
| Current Ratio | 3.031 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.14 |
| Day Low | 1.05 |
| Earnings Call Timestamp End | 1,786,624,200 |
| Earnings Call Timestamp Start | 1,786,624,200 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,313,800 |
| Earnings Timestamp Start | 1,794,313,800 |
| Ebitda | -93,706,496 |
| Ebitda Margins | -1.1774501 |
| Enterprise To Ebitda | -3.864 |
| Enterprise To Revenue | 4.55 |
| Enterprise Value | 362,071,808 |
| Eps Forward | -1.49 |
| Eps Trailing Twelve Months | -0.58 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.13924 |
| Fifty Day Average Change | -0.019240022 |
| Fifty Day Average Change Percent | -0.016888471 |
| Fifty Two Week Change Percent | -63.517918 |
| Fifty Two Week High | 4.98 |
| Fifty Two Week High Change | -3.8600001 |
| Fifty Two Week High Change Percent | -0.7751004 |
| Fifty Two Week Low | 0.78 |
| Fifty Two Week Low Change | 0.34000003 |
| Fifty Two Week Low Change Percent | 0.4358975 |
| Fifty Two Week Range | 0.78 - 4.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,589,808,600,000 |
| Float Shares | 88,561,803 |
| Forward Eps | -1.49 |
| Forward P E | -0.7516779 |
| Free Cashflow | -68,119,872 |
| Full Exchange Name | NYSE |
| Full Time Employees | 188 |
| Fullday Change | 0.0700001 |
| Fullday Change Percent | 6.66667 |
| Fullday Price | 1.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.11594 |
| Gross Profits | -9,227,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14419 |
| Held Percent Institutions | 0.67533994 |
| Implied Shares Outstanding | 127,667,695 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,020-05-15 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. |
| Long Name | ADC Therapeutics SA |
| Market | us_market |
| Market Cap | 142,987,824 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_183083930 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -96,908,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 134,051,079 |
| Number Of Analyst Opinions | 3 |
| Open | 1.05 |
| Operating Cashflow | -102,270,000 |
| Operating Margins | -1.18142 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 41 21 653 02 00 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.8928563 |
| Post Market Price | 1.11 |
| Post Market Time | 1,787,873,407 |
| Previous Close | 1.05 |
| Price Hint | 4 |
| Price To Book | -0.625349 |
| Price To Sales Trailing12 Months | 1.7966906 |
| Profit Margins | -1.21768 |
| Quick Ratio | 2.863 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.8 |
| Region | US |
| Regular Market Change | 0.0700001 |
| Regular Market Change Percent | 6.66667 |
| Regular Market Day High | 1.14 |
| Regular Market Day Low | 1.05 |
| Regular Market Day Range | 1.05 - 1.14 |
| Regular Market Open | 1.05 |
| Regular Market Previous Close | 1.05 |
| Regular Market Price | 1.12 |
| Regular Market Time | 1,787,860,803 |
| Regular Market Volume | 1,402,880 |
| Return On Assets | -0.19565001 |
| Revenue Growth | 0.022 |
| Revenue Per Share | 0.534 |
| Sand P52 Week Change | 0.1890428 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 127,667,695 |
| Shares Percent Shares Out | 0.0484 |
| Shares Short | 6,175,703 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 5,534,142 |
| Short Name | ADC Therapeutics SA |
| Short Percent Of Float | 0.056999996 |
| Short Ratio | 7.04 |
| Source Interval | 15 |
| Symbol | ADCT |
| Target High Price | 5.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 3.33333 |
| Target Median Price | 3.0 |
| Total Cash | 219,107,008 |
| Total Cash Per Share | 1.716 |
| Total Debt | 438,191,008 |
| Total Revenue | 79,584,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.04653 |
| Two Hundred Day Average Change | -1.92653 |
| Two Hundred Day Average Change Percent | -0.6323686 |
| Type Disp | Equity |
| Volume | 1,402,880 |
| Website | https://www.adctherapeutics.com |
| Zip | 1,066 |